This is Noxopharm Limited

A new company aiming to develop a drug to treat cancer in an innovative way that we believe will bring significant change to the management of cancer.


About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug- and radio-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients.

About Noxopharm

NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

About NOX66

NOX66 is an innovative dosage formulation developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form.


CEO Blog

View more

ASX Share Price Chart

Market Cap:
Price Delayed by ~20min

*market cap above based on the number of quoted shares (i.e. non-escrow stock)

Investor Information

Discovery of Idronoxil-C
NOX CEO explains

View more

Latest News

read more